peramivir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals neuraminidase inhibitors 4823 330600-85-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rapivab
  • peramivir hydrate
  • RWJ-270201
  • peramivir
  • BCX-1812
  • rapiacta
Peramivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells.
  • Molecular weight: 328.41
  • Formula: C15H28N4O4
  • CLOGP: -1.31
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 6
  • TPSA: 148.53
  • ALOGS: -2.94
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
fu (Fraction unbound in plasma) 1 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
CL (Clearance) 1.46 mL/min/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability) 0 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PLK1,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 46
kinase-selectivity-class AXL,EIF2AK3,GRK2,MAP2K6,TEK 5
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
April 13, 2018 EMA BIOCRYST UK LIMITED
Dec. 19, 2014 FDA BIOCRYST

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AH03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Neuraminidase inhibitors
FDA MoA N0000175436 Neuraminidase Inhibitors
FDA EPC N0000175524 Neuraminidase Inhibitor
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:52425 EC 3.2.1.18 (<i>exo</i>-α-sialidase) inhibitor
CHEBI has role CHEBI:22587 antiviral agent

Related Drugs by ATC class:

J05AH Neuraminidase inhibitors 3 drugs
laninamivir octanoate hydrateoseltamivirzanamivir

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Influenza indication 6142004 DOID:8469




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.6 acidic
pKa2 12.05 acidic
pKa3 13.73 acidic
pKa4 10.07 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG/20ML (10MG/ML) RAPIVAB BIOCRYST N206426 Dec. 19, 2014 RX SOLUTION INTRAVENOUS 10391075 Feb. 12, 2027 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
200MG/20ML (10MG/ML) RAPIVAB BIOCRYST N206426 Dec. 19, 2014 RX SOLUTION INTRAVENOUS 10391075 Feb. 12, 2027 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
200MG/20ML (10MG/ML) RAPIVAB BIOCRYST N206426 Dec. 19, 2014 RX SOLUTION INTRAVENOUS 8778997 May 7, 2027 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
200MG/20ML (10MG/ML) RAPIVAB BIOCRYST N206426 Dec. 19, 2014 RX SOLUTION INTRAVENOUS 8778997 May 7, 2027 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
200MG/20ML (10MG/ML) RAPIVAB BIOCRYST N206426 Dec. 19, 2014 RX SOLUTION INTRAVENOUS 8778997 May 7, 2027 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sialidase 2 Enzyme Ki 4.25 CHEMBL
Neuraminidase Enzyme INHIBITOR IC50 8.85 CHEMBL DRUG LABEL
Neuraminidase Enzyme INHIBITOR IC50 8.30 CHEMBL DRUG LABEL
Neuraminidase Enzyme INHIBITOR Ki 9.08 CHEMBL DRUG LABEL
Neuraminidase Enzyme IC50 9.40 CHEMBL
Neuraminidase Enzyme IC50 10.15 CHEMBL
Neuraminidase Enzyme IC50 8.70 CHEMBL
Neuraminidase Enzyme IC50 7.03 CHEMBL
Sialidase Enzyme IC50 4.40 CHEMBL
Neuraminidase Enzyme IC50 9.52 CHEMBL

External reference:

IDSource
D03829 KEGG_DRUG
1041434-82-5 SECONDARY_CAS_RN
4034033 VANDF
CHEBI:85196 CHEBI
BCZ PDB_CHEM_ID
CHEMBL3989402 ChEMBL_ID
CHEMBL139367 ChEMBL_ID
C414210 MESH_SUPPLEMENTAL_RECORD_UI
DB06614 DRUGBANK_ID
1598078 RXNORM
231961 MMSL
30814 MMSL
d08335 MMSL
013296 NDDF
716121006 SNOMEDCT_US
763542005 SNOMEDCT_US
C1675326 UMLSCUI
154234 PUBCHEM_CID
QW7Y7ZR15U UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rapivab HUMAN PRESCRIPTION DRUG LABEL 1 61364-181 SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rapivab HUMAN PRESCRIPTION DRUG LABEL 1 72769-181 SOLUTION 600 mg INTRAVENOUS NDA 30 sections